220
Participants
Start Date
October 1, 2016
Primary Completion Date
March 31, 2018
Study Completion Date
March 31, 2018
Feminizing hormone therapy
"Estradiol valerate was initiated at 2 mg PO daily and increased to 4 mg after 4 to 12 weeks~Antiandrogen therapy with spironolactone started at a dose of 50 mg PO daily and increased every 4 weeks to 200 mg daily"
Peer navigation
Transgender women community peer navigation
Epicentro, Lima
Collaborators (1)
The Fenway Institute
OTHER
Epicentro
UNKNOWN
amfAR, The Foundation for AIDS Research
OTHER
Asociación Civil Impacta Salud y Educación, Peru
OTHER